BioSpace News Archive

Results from the largest prospective study of stroke AI software were presented today at the European Stroke Organisation Conference (ESOC) in Basel

According to recent study by Nova one advisor, the U.S. nuclear medicine market size was estimated at USD 5.85 billion in 2023 and is projected to hit around USD 19.34 billion by 2033, growing at a CAGR of 12.7% during the forecast period from 2024 to 2033.

In the dynamic landscape of modern medicine, the emergence of bispecific antibodies stands as a testament to the relentless pursuit of innovation in therapeutic modalities.

Gemelli Biotech and its technologies will be featured in numerous presentations at DDW 2024.

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today reported its revenue for the quarter ended March 31, 2024 and provided a business update.

Orlance, a pioneering Seattle-based biotech company, is thrilled to announce a new development project with esteemed partner Product Creation Studio, a leader in innovative engineering and design services.

Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, to take place on Monday, May 20, 2024, at the NASDAQ World Headquarters New York, NY.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk score can accurately predict the benefit of adding androgen deprivation therapy to radiation therapy in men with localized prostate cancer.

Annexon, Inc. announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22nd, 2024, with a live fireside chat scheduled for 9:00-9:40 am ET.